Accord BioPharma’s Stelara® Biosimilar Imuldosa™ Approved by FDA

Start
On October 10, 2024, the FDA approved Accord BioPharma’s Imuldosa™ (ustekinumab-srlf), the fifth biosimilar of Janssen / Johnson & Johnson’s Stelara® (ustekinumab). Imuldosa™ was developed by Dong-A ST in collaboration with Meij Seika Pharma, and Accord is responsible for commercialization in the U.S….
By: Venable LLP
Previous Story

Worker’s Comp Versus Personal Injury in California

Next Story

Teva’s Denosumab Biosimilar Candidate is Accepted for Review by FDA and EMA